ライフサイエンスコーパス: antibody-dependent cellular cytotoxicity

1 enhancing NK cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.

2 ediated by donor-specific antibodies through antibody-dependent cellular cytotoxicity.

3 us virion capture, virus neutralization, and antibody-dependent cellular cytotoxicity.

4 get IL-5R and attenuate eosinophilia through antibody-dependent cellular cytotoxicity.

5 th IgG Fc-mediated complement activation and antibody-dependent cellular cytotoxicity.

6 ors via complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity.

7 ody for easy-to-neutralize SIV isolates, and antibody-dependent cellular cytotoxicity.

8 r natural killer cells, nor does it diminish antibody-dependent cellular cytotoxicity.

9 ivation of PP2A also decreases human NK-cell antibody-dependent cellular cytotoxicity.

10 diates complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.

11 esponse, presumably because of their role in antibody-dependent cellular cytotoxicity.

12 zing antibody titers and better induction of antibody-dependent cellular cytotoxicity.

13 suggesting that it is mediated by a form of antibody-dependent cellular cytotoxicity.

14 -mediated phagocytosis, oxidative burst, and antibody-dependent cellular cytotoxicity.

15 ents C1q, C3, C5, and properdin and blocking antibody-dependent cellular cytotoxicity.

16 lectivity, as well as, interestingly, higher antibody-dependent cellular cytotoxicity.

17 for immune responses such as phagocytosis or antibody-dependent cellular cytotoxicity.

18 ceptors and hence effector functions such as antibody-dependent cellular cytotoxicity.

19 educed binding to FcgammaRIIIa and decreased antibody-dependent cellular cytotoxicity.

20 ered, B7-H3-targeting antibody that mediates antibody-dependent cellular cytotoxicity.

21 elevated natural cytotoxicity, and increased antibody-dependent cellular cytotoxicity.

22 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

23 ces from diverse HIV-1 isolates and mediated antibody-dependent cellular cytotoxicity.

24 -induced (CD4i) antibodies capable of potent antibody-dependent cellular cytotoxicity.

25 Complement- and antibody-dependent cellular cytotoxicity-activating func

26 te fucose-deficient antibodies with enhanced antibody-dependent cellular cytotoxicity activities.

27 g to FcgammaRIIIA and thereby decreasing the antibody-dependent cellular cytotoxicity activities.

28 High antibody-dependent cellular cytotoxicity activity at the

29 No alteration in gamma-receptor binding and antibody-dependent cellular cytotoxicity activity was ob

30 dy incapable of Fcgamma receptor binding and antibody-dependent cellular cytotoxicity activity, aboli

31 ed with higher serum binding titer, stronger antibody-dependent cellular cytotoxicity activity, and p

32 by generation of reactive oxygen species or antibody-dependent cellular cytotoxicity activity, but l

33 immunoglobulin that may cooperatively elicit antibody-dependent cellular cytotoxicity activity.

34 ons directly contribute to the modulation of antibody-dependent cellular cytotoxicity activity.

35 er, we found no difference in serum in vitro antibody-dependent cellular cytotoxicity activity.

36 tivate multiple effector functions including antibody dependent cellular cytotoxicity (ADCC) and anti

37 versely affect the ability of mAbs to induce antibody dependent cellular cytotoxicity (ADCC).

38 antibodies (Abs), those capable of mediating antibody-dependent cellular cytotoxicity (ADCC) activity

39 oclonal antibodies and subsequently modulate antibody-dependent cellular cytotoxicity (ADCC) activity

40 bodies) show reduced FcgammaR engagement and antibody-dependent cellular cytotoxicity (ADCC) activity

41 n both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) activity

42 the five neutralizing MAbs exhibited strong antibody-dependent cellular cytotoxicity (ADCC) activity

43 (Abs) to the V1V2 region of gp120 with high antibody-dependent cellular cytotoxicity (ADCC) activity

44 is V3 specificity correlated with measurable antibody-dependent cellular cytotoxicity (ADCC) activity

45 and that this protection may correlate with antibody-dependent cellular cytotoxicity (ADCC) activity

46 lobulin G1 antibody variant with compromised antibody-dependent cellular cytotoxicity (ADCC) activity

47 ust cross-clade binding and neutralizing and antibody-dependent cellular cytotoxicity (ADCC) activity

48 ngly, the presence of antibodies with potent antibody-dependent cellular cytotoxicity (ADCC) activity

49 The ALVAC/AIDSVax vaccine induced antibody-dependent cellular cytotoxicity (ADCC) against

50 The antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against

51 Both 42F and 43F directed substantial antibody-dependent cellular cytotoxicity (ADCC) against

52 Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against

53 ility to opsonize viral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against

54 b) directs natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against

55 cantly greater antibody activities mediating antibody-dependent cellular cytotoxicity (ADCC) and anti

56 Antibody-dependent cellular cytotoxicity (ADCC) and anti

57 on-neutralizing antibody functions including antibody-dependent cellular cytotoxicity (ADCC) and anti

58 iminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and anti

59 Antibody-dependent cellular cytotoxicity (ADCC) and comp

60 IgG1 b12 mediated strong antibody-dependent cellular cytotoxicity (ADCC) and comp

61 2 immune functions, cytomegalovirus-specific antibody-dependent cellular cytotoxicity (ADCC) and natu

62 n, Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and phag

63 CD16a triggers antibody-dependent cellular cytotoxicity (ADCC) and phag

64 d recycling, Fc effector activities, such as antibody-dependent cellular cytotoxicity (ADCC) and phag

65 These Treg suppressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and thei

66 HIV-1-specific antibody-dependent cellular cytotoxicity (ADCC) antibodi

67 munodeficiency virus type 1 (HIV-1)-specific antibody-dependent cellular cytotoxicity (ADCC) antibody

68 s immunized by only the i.m. route had lower antibody-dependent cellular cytotoxicity (ADCC) antibody

69 To investigate antibody-dependent cellular cytotoxicity (ADCC) as a con

70 s by competition with ACE2 but could involve antibody-dependent cellular cytotoxicity (ADCC) as IgG1

71 An antibody-dependent cellular cytotoxicity (ADCC) assay wa

72 In vitro antibody-dependent cellular cytotoxicity (ADCC) assays i

73 y-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays w

74 However, in 2 HSV-2 antibody-dependent cellular cytotoxicity (ADCC) assays,

75 phagocytosis, NK cell activation assays, and antibody-dependent cellular cytotoxicity (ADCC) assays.

76 ed cells at all doses and a 52% reduction in antibody-dependent cellular cytotoxicity (ADCC) at doses

77 riggered lysis of multiple myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) but did

78 Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggre

79 ycan fucosylation have been shown to improve antibody-dependent cellular cytotoxicity (ADCC) by allow

80 eptor expressed on NK cells that facilitates antibody-dependent cellular cytotoxicity (ADCC) by bindi

81 ee medium, but had not been shown to inhibit antibody-dependent cellular cytotoxicity (ADCC) by CD16+

82 Fc afucosylation was introduced to enhance antibody-dependent cellular cytotoxicity (ADCC) by Fcgam

83 Antibody-dependent cellular cytotoxicity (ADCC) by immun

84 g antibodies with effector functions such as antibody-dependent cellular cytotoxicity (ADCC) contribu

85 Growing evidence indicates antibody-dependent cellular cytotoxicity (ADCC) contribu

86 The characteristics of antibody-dependent cellular cytotoxicity (ADCC) directed

87 oss-reactive antibodies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) effector

88 ll-sorting (FACS) analysis, and had enhanced antibody-dependent cellular cytotoxicity (ADCC) effector

89 ible (CDi) neutralizing epitopes targeted by antibody-dependent cellular cytotoxicity (ADCC) effector

90 onses at an early time point correlated with antibody-dependent cellular cytotoxicity (ADCC) function

91 Antibody-dependent cellular cytotoxicity (ADCC) has been

92 virus type 1 (HIV-1) Env and able to mediate antibody-dependent cellular cytotoxicity (ADCC) have bee

93 ng evidence supports a role for HIV-specific antibody-dependent cellular cytotoxicity (ADCC) in contr

94 we examined type-specific and cross-reactive antibody-dependent cellular cytotoxicity (ADCC) in HIV-1

95 e HIV-1-infected cells and eliminate them by antibody-dependent cellular cytotoxicity (ADCC) in the p

96 to increase FcgammaRIII binding and improve antibody-dependent cellular cytotoxicity (ADCC) in vitro

97 Although anti-CD52 functions primarily by antibody-dependent cellular cytotoxicity (ADCC) in vivo,

98 -HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversel

99 Antibody-dependent cellular cytotoxicity (ADCC) is a key

100 Antibody-dependent cellular cytotoxicity (ADCC) is media

101 16-mediated NK cell IFN-gamma production and antibody-dependent cellular cytotoxicity (ADCC) is uncle

102 Antibody-dependent cellular cytotoxicity (ADCC) may be a

103 Therefore, antibody-dependent cellular cytotoxicity (ADCC) may play

104 Nonneutralizing antibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may prov

105 and neutrophils for killing of L3 through an antibody-dependent cellular cytotoxicity (ADCC) mechanis

106 Treg depletion was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanis

107 A major mechanism of action of RTX is antibody-dependent cellular cytotoxicity (ADCC) mediated

108 but not natural killer (NK) cells to induce antibody-dependent cellular cytotoxicity (ADCC) of alpha

109 able to induce complement-mediated lysis and antibody-dependent cellular cytotoxicity (ADCC) of trans

110 uce CD16 modulation, CD54 up-regulation, and antibody-dependent cellular cytotoxicity (ADCC) on NK ce

111 Elimination of HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC) requires

112 itopes) as targets of potentially protective antibody-dependent cellular cytotoxicity (ADCC) response

113 ding IgG and IgA as well as neutralizing and antibody-dependent cellular cytotoxicity (ADCC) response

114 mRNA-1647 elicited higher neutralization and antibody-dependent cellular cytotoxicity (ADCC) response

115 The correlation of HIV-specific antibody-dependent cellular cytotoxicity (ADCC) response

116 cellular phagocytosis of HIV-1 virions, and antibody-dependent cellular cytotoxicity (ADCC) response

117 levels of HIV-1-neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) response

118 XmAb5592 increased antibody-dependent cellular cytotoxicity (ADCC) several

119 Antibody-Dependent Cellular Cytotoxicity (ADCC) targetin

120 complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through

121 ith prechallenge serum antienvelope avidity, antibody-dependent cellular cytotoxicity (ADCC) titers,

122 There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to elimi

123 e HIV-1 reservoir.IMPORTANCE Mobilization of antibody-dependent cellular cytotoxicity (ADCC) to elimi

124 protein expressed by infected cells mobilize antibody-dependent cellular cytotoxicity (ADCC) to elimi

125 ed to NCI05, NCI09 mediates higher titers of antibody-dependent cellular cytotoxicity (ADCC) to gp120

126 In the secondary analysis, antibody-dependent cellular cytotoxicity (ADCC) was anot

127 Antibody-dependent cellular cytotoxicity (ADCC) was meas

128 tes biological effector functions, including antibody-dependent cellular cytotoxicity (ADCC) which is

129 ating the factors that modulate HIV-specific antibody-dependent cellular cytotoxicity (ADCC) will hel

130 t PBMC also kill antibody-opsonized cells by antibody-dependent cellular cytotoxicity (ADCC), a react

131 Complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apo

132 d more stem-specific antibodies, with higher antibody-dependent cellular cytotoxicity (ADCC), and bet

133 e breadth of HIV-1 gp120 and V1V2 responses, antibody-dependent cellular cytotoxicity (ADCC), and low

134 The MAbs mediated antibody-dependent cellular cytotoxicity (ADCC), and mic

135 Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and mod

136 cells through effector functions, especially antibody-dependent cellular cytotoxicity (ADCC), antibod

137 b triggers natural killer (NK)-cell-mediated antibody-dependent cellular cytotoxicity (ADCC), but lit

138 rituximab-mediated antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complem

139 s may mediate protective effects by means of antibody-dependent cellular cytotoxicity (ADCC), in whic

140 functions, including tier 1 neutralization, antibody-dependent cellular cytotoxicity (ADCC), infecte

141 ide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is curr

142 hermore, HCD122 is also a potent mediator of antibody-dependent cellular cytotoxicity (ADCC), lysing

143 antibodies (MAbs) frequently mediate potent antibody-dependent cellular cytotoxicity (ADCC), making

144 we demonstrate that XmAb5574 mediates potent antibody-dependent cellular cytotoxicity (ADCC), modest

145 ed up to 3 mg of mAb that possesses enhanced antibody-dependent cellular cytotoxicity (ADCC), nonanti

146 cts on virus infectivity, antibodies mediate antibody-dependent cellular cytotoxicity (ADCC), the kil

147 al of NK cells by NK cell engagers mediating antibody-dependent cellular cytotoxicity (ADCC), thereby

148 infants have significantly higher levels of antibody-dependent cellular cytotoxicity (ADCC), though,

149 ese epitopes and sensitize infected cells to antibody-dependent cellular cytotoxicity (ADCC), we trea

150 e, core fucosylation significantly decreases antibody-dependent cellular cytotoxicity (ADCC), whereas

151 One such mechanism is antibody-dependent cellular cytotoxicity (ADCC), whereby

152 Polymorphonuclear leukocytes (PMNs) mediate antibody-dependent cellular cytotoxicity (ADCC), which i

153 ase of cell reinfection, and protection from antibody-dependent cellular cytotoxicity (ADCC), which i

154 Fc N-glycans leads to drastic enhancement of antibody-dependent cellular cytotoxicity (ADCC), while t

155 Cross-reactive influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activati

156 ed that human natural killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC)-like mec

157 elope glycoproteins is the primary target of antibody-dependent cellular cytotoxicity (ADCC)-mediatin

158 tion with either lineage induces HA-specific antibody-dependent cellular cytotoxicity (ADCC)-mediatin

159 ural killer (NK) cells resulting in crippled antibody-dependent cellular cytotoxicity (ADCC).

160 diminished natural cytotoxicity but enhanced antibody-dependent cellular cytotoxicity (ADCC).

161 lso kills MET-overexpressing cancer cells by antibody-dependent cellular cytotoxicity (ADCC).

162 ve demonstrated that CD4i antibodies mediate antibody-dependent cellular cytotoxicity (ADCC).

163 d NK cell degranulation and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

164 of tumour-infiltrating regulatory T cells by antibody-dependent cellular cytotoxicity (ADCC).

165 ugh Fc receptor-dependent processes, such as antibody-dependent cellular cytotoxicity (ADCC).

166 xtensively studied for its role in mediating antibody-dependent cellular cytotoxicity (ADCC).

167 tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC).

168 through Fc receptors by antibodies mediating antibody-dependent cellular cytotoxicity (ADCC).

169 ed rituximab binding and rituximab-mediated, antibody-dependent cellular cytotoxicity (ADCC).

170 critical role in Fc receptor (FcR)-mediated antibody-dependent cellular cytotoxicity (ADCC).

171 ch antibodies can exert cytotoxic effects is antibody-dependent cellular cytotoxicity (ADCC).

172 One potential mechanism of action involves antibody-dependent cellular cytotoxicity (ADCC).

173 , complement-dependent cell lysis (CDC), and antibody-dependent cellular cytotoxicity (ADCC).

174 human FcgammaRIIIa/CD16a, a key receptor for antibody-dependent cellular cytotoxicity (ADCC).

175 s the target for neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC).

176 lization by antibodies and infected cells to antibody-dependent cellular cytotoxicity (ADCC).

177 on-neutralizing antibodies (nnAbs) mediating antibody-dependent cellular cytotoxicity (ADCC).

178 ormation (State 2A), which is susceptible to antibody-dependent cellular cytotoxicity (ADCC).

179 to the receptor FcgammaRIIIa and subsequent antibody-dependent cellular cytotoxicity (ADCC).

180 lator of sensitivity to Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC).

181 Env to nnAbs and sensitize infected cells to antibody-dependent cellular cytotoxicity (ADCC).

182 uces the susceptibility of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

183 v conformation and affects the efficiency of antibody-dependent cellular cytotoxicity (ADCC).

184 es, possibly owing to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).

185 ncreases susceptibility of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

186 (NK)-cell degranulation and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

187 marily by activating Fc receptors to mediate antibody-dependent cellular cytotoxicity (ADCC).

188 d rafts and is glycoengineered for augmented antibody-dependent cellular cytotoxicity (ADCC).

189 dividuals contain antibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC).

190 Env in this conformation are susceptible to antibody-dependent cellular cytotoxicity (ADCC).

191 inate cells reactivated from latency through antibody-dependent cellular cytotoxicity (ADCC).

192 t complement-dependent cytotoxicity (CDC) or antibody-dependent cellular-cytotoxicity (ADCC), so as t

193 sponses (characterized by increased in vitro antibody-dependent cellular cytotoxicity [ADCC] activity

194 infected cells by natural killer (NK) cells (antibody-dependent cellular cytotoxicity [ADCC]) or comp

195 Antibody-dependent cellular cytotoxicity against ARH-77

196 tosis in the presence of a cross-linker, and antibody-dependent cellular cytotoxicity against B-cell

197 While antibody-dependent cellular cytotoxicity against gp120 d

198 nt, enhances NK-cell direct cytotoxicity and antibody-dependent cellular cytotoxicity against hematop

199 cking core N-glycan residues mediated higher antibody-dependent cellular cytotoxicity against human t

200 An afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+H

201 atural killer cells with concurrent enhanced antibody-dependent cellular cytotoxicity against rituxim

202 ermore, there was no significant increase in antibody-dependent cellular cytotoxicity against SARS-Co

203 fic CD16(pos) gammadelta T cells can perform antibody-dependent cellular cytotoxicity against stromal

204 The CEA-specific antibodies mediated antibody-dependent cellular cytotoxicity against tumor c

205 ed in N. benthamiana are capable of inducing antibody-dependent cellular cytotoxicity, an activity no

206 e that immunostimulatory CpG ODN can enhance antibody dependent cellular cytotoxicity and warrant fur

207 ti-IL1RAP antibody capable of both achieving antibody-dependent cellular cytotoxicity and blocking of

208 pecific monoclonal antibodies display robust antibody-dependent cellular cytotoxicity and CD4-depende

209 y programmed immune responses were driven by antibody-dependent cellular cytotoxicity and complement-

210 nal epitopes and mediated both AQP4-directed antibody-dependent cellular cytotoxicity and complement-

211 oinflammatory direct cell killing to promote antibody-dependent cellular cytotoxicity and complement-

212 osed for this therapeutic antibody including antibody-dependent cellular cytotoxicity and complement-

213 ) can induce lysis of neuroblastoma cells by antibody-dependent cellular cytotoxicity and complement-

214 The antibody-dependent cellular cytotoxicity and complement-

215 tes killing of infected cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-

216 f a CD20-targeting antibody had no impact on antibody-dependent cellular cytotoxicity and did not cha

217 emistry, and a target for cetuximab-mediated antibody-dependent cellular cytotoxicity and in vivo eli

218 different cell surface antigens, but not to antibody-dependent cellular cytotoxicity and lymphokine-

219 ne phosphorylation during the development of antibody-dependent cellular cytotoxicity and natural kil

220 redicted susceptibility to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred in

221 tes immunological effector functions such as antibody-dependent cellular cytotoxicity and phagocytosi

222 ICP(IL2ZA) with RT and mAbs promotes antibody-dependent cellular cytotoxicity and phagocytosi

223 -negative tumor cells were resistant to both antibody-dependent cellular cytotoxicity and signaling-i

224 s including metastases, mediates tumoricidal antibody-dependent cellular cytotoxicity and stimulates

225 In contrast, antibody-dependent cellular cytotoxicity and T cell acti

226 lear leukocytes and macrophages that mediate antibody-dependent cellular cytotoxicity and/or trigger

227 r not only induced gp140-specific IgG, ADCC (antibody-dependent cellular cytotoxicity) and some neutr

228 ion by activating innate immunity, enhancing antibody dependent cellular cytotoxicity, and serving as

229 both macrophage-dependent FcgammaR-mediated antibody-dependent cellular cytotoxicity, and by direct

230 ability of lumiliximab to mediate apoptosis, antibody-dependent cellular cytotoxicity, and complement

231 such as cell signaling, B cell development, antibody-dependent cellular cytotoxicity, and oncogenesi

232 ng of infected targets through direct lysis, antibody-dependent cellular cytotoxicity, and production

233 ate effector pathways, such as phagocytosis, antibody-dependent cellular cytotoxicity, and the recrui

234 arcinoma cells were shown to be sensitive to antibody-dependent cellular cytotoxicity, and their in v

235 P4 internalization, complement-dependent and antibody-dependent cellular cytotoxicity, and water chan

236 le mechanisms including apoptosis induction, antibody-dependent cellular cytotoxicity, antibody-depen

237 c IgG antibody levels after 48 weeks of ART, antibody-dependent cellular cytotoxicity, antibody-depen

238 including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-depen

239 Moreover, in antibody-dependent cellular cytotoxicity assays against

240 Antibody-dependent cellular cytotoxicity assays using pu

241 odification in the Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically r

242 gest that enhancement of Fc gamma R-mediated antibody-dependent cellular cytotoxicity by inflammatory

243 ivation of the classical complement pathway, antibody-dependent cellular cytotoxicity by innate immun

244 ts from a panel of exploratory immunoassays (antibody-dependent cellular cytotoxicity, CD4+ T-cell cy

245 proved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with r

246 The 20-2b shows enhanced antibody-dependent cellular cytotoxicity compared with v

247 uce Fc-mediated effector functions including antibody-dependent cellular cytotoxicity, complement-dep

248 Antibody Fc-mediated functions, such as antibody-dependent cellular cytotoxicity, contribute to

249 pe glycans and reported to display increased antibody-dependent cellular cytotoxicity, demonstrates t

250 s, of which the major mechanism of action is antibody-dependent cellular cytotoxicity (eg, trastuzuma

251 he asymmetrically engineered Fc variants for antibody-dependent cellular cytotoxicity enhancement cou

252 an anti-CD38 monoclonal antibody in reverse antibody-dependent cellular cytotoxicity experiments, it

253 The in vivo half-life, antibody-dependent cellular cytotoxicity function, and b

254 Specific killing of C15 cells in in vitro antibody-dependent cellular cytotoxicity has been observ

255 ation and degradation and mediates effective antibody-dependent cellular cytotoxicity in a variety of

256 igh-affinity, non-cleavable CD16 to optimise antibody-dependent cellular cytotoxicity in combination

257 ing of CD16 (Fc gamma RIIIA), which mediates antibody-dependent cellular cytotoxicity in LAKs, also l

258 These include activation of antibody-dependent cellular cytotoxicity, inhibition of

259 Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity involving Fcgam

260 3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoprolifer

261 This can likely be ascribed to the antibody-dependent cellular cytotoxicity machinery becau

262 FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more imp

263 We consider two alternatives: the first, antibody-dependent cellular cytotoxicity mediated by FcR

264 2M activates natural killer cells to enhance antibody-dependent cellular cytotoxicity, mediates compl

265 ) arm that was derived from broadly binding, antibody-dependent cellular cytotoxicity-mediating antib

266 highest titers of binding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antib

267 ecific MAbs that showed Galcer blocking, the antibody-dependent cellular cytotoxicity-mediating CH38

268 Our study highlights the potential role that antibody-dependent cellular cytotoxicity might play in a

269 gocytosis of antibody-coated tachyzoites nor antibody-dependent cellular cytotoxicity nor antibody-an

270 diates complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity of CD20-positiv

271 dy inhibits cell growth and induces in vitro antibody-dependent cellular cytotoxicity of human neurob

272 ne neutralization of RANKL with induction of antibody-dependent cellular cytotoxicity of natural kill

273 3H and C275Y, decreased binding affinity and antibody-dependent cellular cytotoxicity of the commerci

274 Unlike rituximab, hLL1 did not induce antibody-dependent cellular cytotoxicity or complement-m

275 mulation, by the use of antibodies to induce antibody-dependent cellular cytotoxicity or to block iKI

276 d functional activity (virus neutralization, antibody-dependent cellular cytotoxicity, phagocytosis,

277 an HIV-1 Env vaccine increased C1C2-specific antibody-dependent cellular cytotoxicity potency and bre

278 nses can be induced through the induction of antibody-dependent cellular cytotoxicity, promotion of a

279 NSCC sensitivity in a manner associated with antibody-dependent cellular cytotoxicity rather than EGF

280 which eosinophils mediate tissue injury and antibody-dependent cellular cytotoxicity reactions.

281 levels of IgA antibodies, and high levels of antibody-dependent cellular cytotoxicity responses and H

282 Adaptive NK cells dominated antibody-dependent cellular cytotoxicity responses, and

283 In each study, protection correlated with antibody-dependent cellular cytotoxicity specific for CD

284 were highly functional and displayed greater antibody-dependent cellular cytotoxicity than CD56(dim)

285 1 Fc protein variant that exhibited enhanced antibody-dependent cellular cytotoxicity, the lack of fu

286 FR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increa

287 They can mediate antibody-dependent cellular cytotoxicity to eradicate tu

288 f natural killer cells, the key mediators of antibody-dependent cellular cytotoxicity, to human AMR i

289 ariety of rodent tumor models by stimulating antibody-dependent cellular cytotoxicity toward tumor ve

290 sis of Fc gamma R+ target cells in a reverse antibody-dependent cellular cytotoxicity-type assay and

291 Enhancement of antibody-dependent cellular cytotoxicity was also observ

292 a generalized defect in cytotoxicity because antibody-dependent cellular cytotoxicity was intact.

293 Antibody-dependent cellular cytotoxicity was not require

294 IFN-gamma treatment of monocytes enhanced antibody-dependent cellular cytotoxicity, whereas IFN-ga

295 g CD16a (also known as FcgammaRIIIa) mediate antibody-dependent cellular cytotoxicity, whereas loss o

296 IgG are potent effectors of complement- and antibody-dependent cellular cytotoxicity, which are crit

297 ly infected cells through mechanisms such as antibody-dependent cellular cytotoxicity, which may redu

298 biting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests

299 In addition, the antibodies did not manifest antibody-dependent cellular cytotoxicity with NOD/SCID s

300 ctor functionality often focus on maximizing antibody-dependent cellular cytotoxicity, yet distinct c